anti-ccr8 antibody-drug conjugate tak-188
Generic: Anti-CCR8 Antibody-drug Conjugate TAK-188
anti-ccr8 antibody-drug conjugate tak-188: 1 clinical trial tracked.
anti-ccr8 antibody-drug conjugate tak-188 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-ccr8 antibody-drug conjugate tak-188, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Primary endpoint: Phase 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Interventionalopen223 targetStarted 2025-11Completion 2029-1215 sites · United StatesTakeda